WO2002030501A1 - Production d"un aérosol au moyen d"une membrane frangible - Google Patents
Production d"un aérosol au moyen d"une membrane frangible Download PDFInfo
- Publication number
- WO2002030501A1 WO2002030501A1 PCT/GB2001/004476 GB0104476W WO0230501A1 WO 2002030501 A1 WO2002030501 A1 WO 2002030501A1 GB 0104476 W GB0104476 W GB 0104476W WO 0230501 A1 WO0230501 A1 WO 0230501A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery device
- diaphragm
- medicament
- aerosol delivery
- aerosol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/075—Bulb type
Definitions
- This invention relates to a novel form of diaphragm and to devices comprising the novel diaphragm.
- medicaments administered by inhalation may be administered in the form of a dry powder with the use of a dry powder inhaler (DPI) or in the form of a solution or suspension with the use of a pressurised metered dose inhaler (MDI).
- DPI dry powder inhaler
- MDI pressurised metered dose inhaler
- a holding chamber such that an aerosolised medicament is dispensed from an inhaler and the medicament is momentarily held in the chamber before the patient inhales.
- One disadvantage of such holding chambers is that, due to, inter alia, electrostatic charges, agglomeration of the aerosolised particles may occur and/or particles may be attached to the surfaces of the chamber.
- US Patent No 5,349,947 describes a powder inhaler which comprises pillows or a blister type contained which, in use, is compressed between an anvil and piston, such that when the pillow is compressed the pillow is explosively ruptured, causing the gas and medicament encased in the pillow to escape at very high speed
- a powder inhaler which comprises pillows or a blister type contained which, in use, is compressed between an anvil and piston, such that when the pillow is compressed the pillow is explosively ruptured, causing the gas and medicament encased in the pillow to escape at very high speed
- disadvantage with such an inhaler system is that, inter alia, prior to rupture of the pillow, the compression of the gas within the pillow may also lead to compression of the medicament powder within the pillow.
- a --Tangible diaphragm is especially suitable for generating a powder and air mixture, e.g. an aerosol, and which overcomes the aforementioned disadvantage of the prior art. Therefore, such a frangible diaphragm especially finds utility in a medicament delivery device, such as an inhaler, e.g. a dry powder inhaler (DPI) and may be suited to the delivery of a medicament into, for example, a holding chamber.
- an inhaler e.g. a dry powder inhaler (DPI)
- DPI dry powder inhaler
- a method of producing an aerosol which comprises placing a dispersible material adjacent to a first surface of a frangible diaphragm, applying a pressure differential across the diaphragm so that the pressure on the first side of the diaphragm adjacent to the dispersible material is less than that on the second side of the diaphragm distal to the material such that when the diaphragm ruptures the released pressure acts to disperse the material away from the diaphragm.
- the dispersible material should be adjacent the frangible diaphragm in order to overcome the disadvantages of the prior art, the material should be remote from the frangible diaphragm.
- the frangible diaphragm should have only minimal fluid, e.g. gas permeability, thus enabling a pressure to be built against the second surface of the diaphragm.
- the diaphragm therefore preferentially comprises a substantially non-gas permeable material.
- a substantially non-gas permeable material may be a plastics material or a metal foil, e.g. aluminium foil.
- the frangibly closed end preferably comprises a frangible diaphragm as hereinbefore described.
- the means for delivering the material may comprise conventionally known means.
- Such means preferentially comprises a metering member.
- the means may comprise a bulk powder reservoir in conjunction with a metering member.
- the means may comprise a metering member with a predetermined amount of powder material.
- the powder delivery means comprises a spool housed in a spool carrier.
- Each spool is provided with a flange at each end.
- the flanges forming a tight slidable fit within the body of the spool carrier.
- the space left between the body of the spool and the spool carrier is filled with an appropriate power material.
- the system of the invention has utility in a variety of areas, including, for example, medicament delivery devices, such as inhalers; air fresheners or any other devices which rely upon an aerosol generation and especially a powder aerosol.
- medicament delivery devices such as inhalers
- air fresheners or any other devices which rely upon an aerosol generation and especially a powder aerosol.
- the system of the present invention is especially suited for use in conjunction with an inhaler, including an MDI, a DPI, an insufflator and a nebuliser.
- the inhaler of the invention comprises a DPI.
- a delivery system as hereinbefore described wherein the powder material is a medicament optionally including carrier material.
- a medicament delivery device which comprises a medicament reservoir, a metering mechanism and a medicament outlet characterised in that the delivery device is provided with a frangible diaphragm as hereinbefore described and with means for creating a pressure differential across the diaphragm.
- the medicament reservoir may be a bulk reservoir, in which a separate metering mechanism is provided. Such an arrangement is described in International Patent application No. WO 92/00771, which is incorporated herein by reference. Alternatively, if the medicament reservoir comprises unit dosage means, then the medicament reservoir and metering mechanism may comprise a single unit. Such an arrangement is described in European Patent No. 664 239, which is also incorporated herein by reference.
- the medicament delivery device is an inhaler.
- the medicament delivery means is adapted to be positioned adjacent to the frangible diaphragm.
- a predetermined amount of medicament may be housed in a delivery unit, such as a spool carrier and thus the medicament is exposed when the metering mechanism is actuated.
- Pressure may be introduced by an increase in pressure on the surface of the diaphragm remote from the medicament delivery member.
- a vacuum may be applied to the first surface of the diaphragm. When the pressure vacuum reaches a predetermined level, the diaphragm breaks allowing a rush of air to flow through the diaphragm towards the outlet and mixing with the medicament.
- the medicament may be positioned such that it rests on the frangible diaphragm.
- the change in pressure may be mechanically or electromechanically actuated.
- the increase in pressure may be actuated manually, for example, by the use of a flexible portion of the inhaler.
- the pressure may be introduced by an increase in pressure on the non-dispensing surface of the frangible member or, alternatively, by a decrease in pressure on the dispensing surface of the frangible member, e.g. when a patient inhales.
- the actuation of the metering mechanism and the breaking of the frangible diaphragm may occur simultaneously separately or sequentially.
- the inhaler of the invention may be provided with a holding chamber.
- This may be a holding chamber which is conventionally known per se.
- it may be an electrically charged holding chamber such as is described in our co-pending applications Nos. GB 0010742.5 and GB 001743.2.
- the inhaler of the invention may optionally include a conventionally known breath actuated mechanism.
- the particle size of the medicament may be varied depending, inter alia, on the type of aerosol being formed.
- the particle size of the medicament, and the carrier, if one is present, may be varied.
- the nature of the carrier may also be varied.
- the particle size of the medicament may be substantially between 1 and 100 ⁇ m. That is, at least 90% w/w of the medicament should have a particle size of between 1 and 100 ⁇ m.
- the preferred particle size may also depend upon the nature of the medicament being delivered. Thus, for example, for the treatment of respiratory disorders a particle size of 4 to 8 ⁇ m may be preferred, e.g. 6 ⁇ m. However, for the delivery of systematically active medicaments a smaller particle size may be desirable, for example from 1 to 5 ⁇ m, e.g. 3 ⁇ m.
- a variety of carriers may be used.
- Certain carriers may be mentioned, by way of example only, such as sugars, e.g. dextran, mannitol and lactose, for example ⁇ -lactose monohydrate.
- the particle size of the carrier may be across a wide range, between 0.1 and 500 ⁇ m, preferably between 1 and 200 ⁇ m, more preferably between 1 and 100 ⁇ m and especially between 1 and 20 ⁇ m.
- the carrier may itself comprise a mixture of fine and coarse particles.
- a method of drug delivery to a patient which comprises administering a medicament to a patient suffering a respiratory disorder which comprises administering a therapeutically effective amount of a medicament using an inhaler as hereinbefore described.
- the inhaler of the invention is advantageous in that, z ' rcter alia, it enables the delivery of dispersions of finely divided forms of medicament and avoids some if the disadvantageous of agglomeration experienced with some known DPIs.
- medicaments may be administered by using the inhaler of the invention, such medicaments may have a systemic or non-systemic activity on the patient.
- medicaments are generally (but not limiting) antibiotics, bronchodilators or other anti-asthma drugs.
- medicaments include, but are not limited to ⁇ 2 -agomsts, e.g. fenoterol, formoterol, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol and terbutaline; non-selective beta-stimulants such as isoprenaline; xanthine bronchodilators, e.g.
- anticholinergics e.g. ipratropium bromide
- mast cell stabilisers e.g. sodium cromoglycate and ketotifen
- bronchial anti-inflammatory agents e.g. nedocromil sodium
- steroids e.g. beclomethasone dipropionate, fluticasone, budesonide and flunisolide; and combinations thereof.
- medicaments which may be mentioned include combinations of steroids, such as, beclomethasone dipropionate, fluticasone, budesonide and flunisolide; and combinations of to ⁇ 2 -agonists, such as, formoterol and salmeterol. It is also within the scope of this invention to include combinations of one or more of the aforementioned steroids with one or more of the aforementioned ⁇ -agonists.
- a method of treating a patient with a respiratory disorder which comprises administering a therapeutically effective amount of a medicament using an inhaler as hereinbefore described.
- medicaments which may be mentioned include systemically active materials, such as, proteinaceous compounds and/or macromolecules, for example, leuprolide and alpha interferon; growth factors, anticoagulants, immunomodulators, cytokines, nucleic acids, hormones, such as insulin human growth hormone and parathyroid hormone.
- systemically active materials such as, proteinaceous compounds and/or macromolecules, for example, leuprolide and alpha interferon
- growth factors such as, proteinaceous compounds and/or macromolecules, for example, leuprolide and alpha interferon
- growth factors such as, anticoagulants, immunomodulators, cytokines, nucleic acids, hormones, such as insulin human growth hormone and parathyroid hormone.
- Figure 1 is a perspective cutaway representation of a cartridge of the invention with the medicament dispensing member in the open position;
- FIG 2 is a perspective, cut away, representation of the invention in the dispensing position.
- a cartridge (1) comprises an open and (2) and a closed end (3).
- the closed end (3) is provided with a frangible diaphragm (4) comprising a first surface (5) and a second surface (6).
- the second surface (6) is positioned adjacent a pressure delivery conduit (7) whilst the first surface (5) is positioned adjacent, a medicament dehvery member (8).
- the medicament delivery member (8) comprises a spool (9) and a spool carrier (10) and is preferentially remote from the first surface (5) of the diaphragm (4).
- the spool (9) is provided with flanges (11 and 12) at either end and holds a cake of medicament (13).
- the cartridge (1) is provided with a spool rest (14).
- the spool In use the spool is ejected from the spool counter (10) exposing the cake of medicament (13).
- One flange (11) of the spool (9) rests in the spool rest (14).
- Pressure is applied to the second surface (6) of the frangible diaphragm (4).
- the diaphragm (4) breaks allowing a rush of air through the cartridge (1). The rush of air deagglomerates the medicament cake (13) and creates a powder aerosol which can be inhaled by a patient.
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001293974A AU2001293974A1 (en) | 2000-10-10 | 2001-10-10 | Aerosol production using a frangible diaphragm |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0024793.2A GB0024793D0 (en) | 2000-10-10 | 2000-10-10 | Diaphragm |
GB0024793.2 | 2000-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002030501A1 true WO2002030501A1 (fr) | 2002-04-18 |
Family
ID=9900998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/004476 WO2002030501A1 (fr) | 2000-10-10 | 2001-10-10 | Production d"un aérosol au moyen d"une membrane frangible |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001293974A1 (fr) |
GB (1) | GB0024793D0 (fr) |
WO (1) | WO2002030501A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8448534B2 (en) | 2007-05-18 | 2013-05-28 | Malvern Instruments Incorporated | Method and apparatus for dispersing a sample of particulate material |
US9179691B2 (en) | 2007-12-14 | 2015-11-10 | Aerodesigns, Inc. | Delivering aerosolizable food products |
WO2015127147A3 (fr) * | 2014-02-21 | 2015-12-10 | David Brown | Dispositif d'inhalation et procédé permettant d'inhaler des poudres |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH518744A (de) * | 1970-01-30 | 1972-02-15 | Ciba Geigy Ag | Vorrichtung zur Applikation von pulverförmigen Substanzen |
WO1992000771A1 (fr) | 1990-07-13 | 1992-01-23 | Innovata Biomed Limited | Inhalateur |
US5215221A (en) * | 1992-05-07 | 1993-06-01 | The Procter & Gamble Company | Disposable unit dose dispenser for powdered medicants |
WO1993016748A2 (fr) | 1992-02-21 | 1993-09-02 | Innovata Biomed Limited | Dispositif de dosage |
US5349947A (en) | 1993-07-15 | 1994-09-27 | Newhouse Michael T | Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow |
WO2001000263A2 (fr) * | 1999-06-30 | 2001-01-04 | Inhale Therapeutic Systems, Inc. | Systemes et procedes de projection par aerosols de formulations pharmaceutiques |
WO2001003578A2 (fr) | 1999-07-14 | 2001-01-18 | Cardiac Pacemakers, Inc. | Classification de signaux au moyen d'algorithme de chronomretrage de canaux croises |
-
2000
- 2000-10-10 GB GBGB0024793.2A patent/GB0024793D0/en not_active Ceased
-
2001
- 2001-10-10 AU AU2001293974A patent/AU2001293974A1/en not_active Abandoned
- 2001-10-10 WO PCT/GB2001/004476 patent/WO2002030501A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH518744A (de) * | 1970-01-30 | 1972-02-15 | Ciba Geigy Ag | Vorrichtung zur Applikation von pulverförmigen Substanzen |
WO1992000771A1 (fr) | 1990-07-13 | 1992-01-23 | Innovata Biomed Limited | Inhalateur |
WO1993016748A2 (fr) | 1992-02-21 | 1993-09-02 | Innovata Biomed Limited | Dispositif de dosage |
US5215221A (en) * | 1992-05-07 | 1993-06-01 | The Procter & Gamble Company | Disposable unit dose dispenser for powdered medicants |
US5349947A (en) | 1993-07-15 | 1994-09-27 | Newhouse Michael T | Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow |
WO2001000263A2 (fr) * | 1999-06-30 | 2001-01-04 | Inhale Therapeutic Systems, Inc. | Systemes et procedes de projection par aerosols de formulations pharmaceutiques |
WO2001003578A2 (fr) | 1999-07-14 | 2001-01-18 | Cardiac Pacemakers, Inc. | Classification de signaux au moyen d'algorithme de chronomretrage de canaux croises |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8448534B2 (en) | 2007-05-18 | 2013-05-28 | Malvern Instruments Incorporated | Method and apparatus for dispersing a sample of particulate material |
US9179691B2 (en) | 2007-12-14 | 2015-11-10 | Aerodesigns, Inc. | Delivering aerosolizable food products |
WO2015127147A3 (fr) * | 2014-02-21 | 2015-12-10 | David Brown | Dispositif d'inhalation et procédé permettant d'inhaler des poudres |
CN106255524A (zh) * | 2014-02-21 | 2016-12-21 | 大卫·布朗 | 用于吸入粉体的吸入装置和方法 |
JP2017506106A (ja) * | 2014-02-21 | 2017-03-02 | ブラウン、デイビッド | 粉末を吸入するための吸入デバイス及び方法 |
CN106255524B (zh) * | 2014-02-21 | 2020-03-24 | 大卫·布朗 | 用于吸入粉体的吸入装置 |
US10857315B2 (en) | 2014-02-21 | 2020-12-08 | David Brown | Inhalation device and method for inhaling powders |
Also Published As
Publication number | Publication date |
---|---|
GB0024793D0 (en) | 2000-11-22 |
AU2001293974A1 (en) | 2002-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0938907B1 (fr) | Inhalateur | |
JP4423036B2 (ja) | アセンブリ | |
KR100474448B1 (ko) | 분말형 약품을 위한 저장 시스템 및 이 시스템을 구비한흡입기 | |
EP1744800B1 (fr) | Inhalateur | |
US8025051B2 (en) | Delivery device | |
US6098619A (en) | Unit dose inhaler apparatus and method of delivery using same | |
US6845772B2 (en) | Inhaler | |
EP1390091B1 (fr) | Dispositif | |
US20090250058A1 (en) | Inhalation System and Delivery Device for the Administration of a Drug in the Form of Dry Powder | |
HU216405B (hu) | Hordozóelem por alakú gyógyszerek adagolására szolgáló inhalálókészülékhez | |
US20120125331A1 (en) | Dry powder inhaler with aeroelastic dispersion mechanism | |
US20110174306A1 (en) | Dry Powder Inhalers with Multi-Facet Surface Deagglomeration Chambers and Related Devices and Methods | |
US20130025593A1 (en) | Dry powder inhaler | |
SK4762002A3 (en) | Medicament delivery device with moisture resistant coating | |
US20060076010A1 (en) | Drug delivery system with vented mouthpiece | |
WO2002030501A1 (fr) | Production d"un aérosol au moyen d"une membrane frangible | |
WO2008139490A2 (fr) | Inhalateur de poudre sèche à multiples doses | |
WO2002089883A1 (fr) | Dispositif de distribution pour une substance fluide | |
WO2002091293A1 (fr) | Mecanisme de comptage | |
WO2002011894A1 (fr) | Diaphragme | |
WO2002089884A1 (fr) | Systeme medical d'administration d'aerosols active par la respiration | |
WO1999056807A1 (fr) | Appareil d'inhalation par dose unitaire et procede de distribution a l'aide de ce dernier | |
RU2258539C1 (ru) | Порошковый ингалятор |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2001/010048 Country of ref document: MX |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |